Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
188.83
-3.40 (-1.77%)
At close: Jun 2, 2026, 4:00 PM EDT
189.00
+0.17 (0.09%)
After-hours: Jun 2, 2026, 7:34 PM EDT
Biogen Revenue
Biogen had revenue of $2.48B in the quarter ending March 31, 2026, with 1.93% growth. This brings the company's revenue in the last twelve months to $9.94B, up 1.23% year-over-year. In the year 2025, Biogen had annual revenue of $9.89B with 2.22% growth.
Revenue (ttm)
$9.94B
Revenue Growth
+1.23%
P/S Ratio
2.81
Revenue / Employee
$1,324,987
Employees
7,500
Market Cap
27.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.89B | 214.70M | 2.22% |
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | 14.38B | 925.00M | 6.88% |
| Dec 31, 2018 | 13.45B | 1.18B | 9.61% |
| Dec 31, 2017 | 12.27B | 825.10M | 7.21% |
| Dec 31, 2016 | 11.45B | 685.00M | 6.36% |
| Dec 31, 2015 | 10.76B | 1.06B | 10.93% |
| Dec 31, 2014 | 9.70B | 2.77B | 39.97% |
| Dec 31, 2013 | 6.93B | 1.42B | 25.66% |
| Dec 31, 2012 | 5.52B | 467.83M | 9.27% |
| Dec 31, 2011 | 5.05B | 332.21M | 7.04% |
| Dec 31, 2010 | 4.72B | 339.07M | 7.75% |
| Dec 31, 2009 | 4.38B | 279.84M | 6.83% |
| Dec 31, 2008 | 4.10B | 925.89M | 29.19% |
| Dec 31, 2007 | 3.17B | 488.57M | 18.21% |
| Dec 31, 2006 | 2.68B | 260.55M | 10.76% |
| Dec 31, 2005 | 2.42B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 63.32B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
| GSK plc | 43.29B |
| Amgen | 37.22B |
BIIB News
- 1 day ago - Biogen, UCB publishes full results from PHOENYCS GO clinical trial in The Lancet - TheFly
- 1 day ago - UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus - GlobeNewsWire
- 6 days ago - Biogen price target raised to $227 from $222 at RBC Capital - TheFly
- 6 days ago - Italy's antitrust regulator opens probe into US Biogen over alleged dominant position - Reuters
- 12 days ago - Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
- 12 days ago - Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints - TheFly
- 12 days ago - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease - GlobeNewsWire
- 18 days ago - Biogen resumed with an Outperform at Evercore ISI - TheFly